Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;14(4):310-1.
doi: 10.1007/s12603-010-0070-5.

Dose ranging for trials through biomarkers of drug effects

W Z Potter  1
Affiliations

Dose ranging for trials through biomarkers of drug effects

W Z Potter. J Nutr Health Aging. 2010 Apr.

Abstract

To test the hypothesis that excess amyloid deposition is an essential step in the pathophysiology of Alzheimer's disease appropriate biomarkers are essential in selecting agents that modify amyloid formation or clearance. Cerebrospinal fluid concentrations of relevant analytes and PET measures of total brain load have been developed. These are directly applied to testing whether drugs reduce various soluble forms of amyloid as well as whether they enhance elimination of material deposited in brain parenchyma. The ideal profile of a drug that can fully test the amyloid hypothesis can be understood in terms of effects on currently available and future biomarkers. Dose selection for clinical trials should require a quantitative threshold effect on the most relevant biomarker.

PubMed Disclaimer

References

    1. Miller G. Neuroscience Methods, Alzheimer’s biomarker initiative hits its stride. Science. 2009;326:386–389. 10.1126/science.326_386 PubMed PMID: 19833956. - DOI - PubMed
    1. Siemers E., Skinner M., Dean R.A., Gonzales C., Satterwhite J., Farlow M., Ness D., May P.C. Safety, tolerability, and changes in amyloid ? concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005;28:126–132. 10.1097/01.wnf.0000167360.27670.29 PubMed PMID: 15965311. - DOI - PubMed
    1. Rosen L.B., Stone J.A., Plump A., Yuan J., Harrison T., Flynn M., Dallob A., Matthews C., Stevenson D., Schmidt D., et al. O4-03-02: The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimer’s and Dementia. 2006;2:S79. 10.1016/j.jalz.2006.05.310 - DOI
    1. Bateman R.J., Siemers E.R., Mawuenyega K.G., Wen G., Browning K.R., Sigurdson W.C., Yarasheski K.E., Friedrich S.W., Demattos R.B., May P.C., et al. A gamma-secretase inhibitor decreases amyloid-production in the central nervous system. Ann Neurol. 2009;66:48–54. 10.1002/ana.21623 PubMed PMID: 19360898. - DOI - PMC - PubMed
    1. Yan P., Bero A.W., Cirrito J.R., Xiao Q., Hu X., Want Y., Gonzales E., Holtzman D.M., Lee J.-M. Characterizing the appearance and growth of amyloid plagues in APP/PS1 mice. J Neurosci. 2009;29:10706–10714. 10.1523/JNEUROSCI.2637-09.2009 PubMed PMID: 19710322. - DOI - PMC - PubMed

MeSH terms